Fate Therapeutics, Inc.
FATE
$2.44
-$0.06-2.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.18% | -20.26% | -26.40% | -43.36% | -71.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.18% | -20.26% | -26.40% | -43.36% | -71.84% |
| Cost of Revenue | -11.09% | -15.21% | -44.60% | -25.43% | -20.73% |
| Gross Profit | 12.61% | 14.92% | 46.82% | 23.69% | 8.30% |
| SG&A Expenses | -22.86% | -30.33% | -19.66% | -48.86% | -33.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.56% | -20.07% | -28.40% | -34.22% | -25.03% |
| Operating Income | 15.78% | 20.06% | 28.48% | 33.68% | 18.00% |
| Income Before Tax | 11.48% | 17.03% | 37.92% | 32.36% | 11.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.48% | 17.03% | 37.92% | 32.36% | 11.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.48% | 17.03% | 37.92% | 32.36% | 11.34% |
| EBIT | 15.78% | 20.06% | 28.48% | 33.68% | 18.00% |
| EBITDA | 15.84% | 20.73% | 27.58% | 34.04% | 16.53% |
| EPS Basic | 12.84% | 18.19% | 38.67% | 33.05% | 12.14% |
| Normalized Basic EPS | 12.85% | 18.18% | 17.43% | 33.04% | 12.13% |
| EPS Diluted | 12.84% | 18.19% | 38.67% | 33.05% | 12.14% |
| Normalized Diluted EPS | 12.85% | 18.18% | 17.43% | 33.04% | 12.13% |
| Average Basic Shares Outstanding | 1.58% | 1.40% | 1.23% | 1.04% | 0.90% |
| Average Diluted Shares Outstanding | 1.58% | 1.40% | 1.23% | 1.04% | 0.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |